eClinical Technology and Industy News

Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD

Excerpt from the Press Release:

WALTHAM, Mass., July 09, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced positive results from its full phase 1 clinical trial for MORF-057, an oral small molecule inhibitor of the α4β7 integrin in development for the treatment of inflammatory bowel disease (IBD). The data were shared today in an ePoster presentation at the Congress of European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress. The additional data shared today include detail regarding the safety, pharmacokinetic (PK) and pharmacodynamic (PD) performance of MORF-057 in healthy subjects.

“The complete phase 1 clinical data set including a favorable safety profile, predictable PK and excellent PD results, confirm MORF-057 as a very strong candidate for oral therapy in inflammatory bowel disease. Notably, MORF-057’s substantial effect on α4β7-expressing lymphocyte migration and CCR9 transcripts in a short two-week dosing period in healthy subjects provides evidence of the selective blockage of lymphocyte homing, a well-validated mechanism for combating the pathological inflammation in IBD,” said Peter Linde, M.D., chief medical officer at Morphic Therapeutic. “We have high confidence as we prepare for a MORF-057 phase 2 clinical program in patients with ulcerative colitis. Our increased conviction is based on the expanded safety profile and even stronger RO data reported today, in combination with biomarker data which we believe provide us with strong evidence of proof of biology.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives